Corona Remedies Ltd vs Gennex Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Corona Remedies Ltd is ₹ 1580 as of 19 Feb 10:41 . The P/E Ratio of Corona Remedies Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Gennex Laboratories Ltd changed from 12.2 on March 2021 to 15.1 on March 2025 . This represents a CAGR of 4.36% over 5 years The Market Cap of Corona Remedies Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Gennex Laboratories Ltd changed from ₹ 49.46 crore on March 2021 to ₹ 274.07 crore on March 2025 . This represents a CAGR of 40.84% over 5 years The revenue of Corona Remedies Ltd for the Dec '25 is ₹ 344.68 crore as compare to the Sep '25 revenue of ₹ 363.57 crore. This represent the decline of -5.2% The revenue of Gennex Laboratories Ltd for the Dec '25 is ₹ 42.96 crore as compare to the Sep '25 revenue of ₹ 39.3 crore. This represent the growth of 9.31% The ebitda of Corona Remedies Ltd for the Dec '25 is ₹ 66.32 crore as compare to the Sep '25 ebitda of ₹ 80.91 crore. This represent the decline of -18.03% The ebitda of Gennex Laboratories Ltd for the Dec '25 is ₹ 8.27 crore as compare to the Sep '25 ebitda of ₹ 7.56 crore. This represent the growth of 9.39% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 41.27 crore over 7 quarters. This represents a CAGR of 20.11% The net profit of Gennex Laboratories Ltd changed from ₹ 4.66 crore to ₹ 5.99 crore over 7 quarters. This represents a CAGR of 15.43% The Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 yearsThe Dividend Payout of Gennex Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

About Gennex Laboratories Ltd

Gennex Laboratories Limited, formerly known as Prudential Pharmaceuticals Limited was incorporated on June 25, 1985.
The Company got converted into a Public Limited Company and the name was changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited in 2007. The Company is in the business of Manufacturing of Bulk Drugs, Intermediates and Biotech Products.
The Company has over the years added more capacity and infrastructure by way of an additional production block and equipment to the plant to handle more products and tonnages.
The Company is having a professionally managed team at every stage of its operations. Apart from these, Gennex is among the leading Vertically Integrated' pharmaceutical companies in India and has a robust product portfolio spread over major product segments encompassing Expectorants, Muscle Relaxants, Analgesic and Anti Fungal.

FAQs for the comparison of Corona Remedies Ltd and Gennex Laboratories Ltd

Which company has a larger market capitalization, Corona Remedies Ltd or Gennex Laboratories Ltd?

Market cap of Corona Remedies Ltd is 10,550 Cr while Market cap of Gennex Laboratories Ltd is 242 Cr

What are the key factors driving the stock performance of Corona Remedies Ltd and Gennex Laboratories Ltd?

The stock performance of Corona Remedies Ltd and Gennex Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Corona Remedies Ltd and Gennex Laboratories Ltd?

As of May 4, 2026, the Corona Remedies Ltd stock price is INR ₹1725.0. On the other hand, Gennex Laboratories Ltd stock price is INR ₹9.99.

How do dividend payouts of Corona Remedies Ltd and Gennex Laboratories Ltd compare?

To compare the dividend payouts of Corona Remedies Ltd and Gennex Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.